Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Hironori Kikkawa"'
Autor:
Yasushi Goto, MD, PhD, Hirotsugu Kenmotsu, MD, PhD, Motohiro Tamiya, MD, Shuji Murakami, MD, Takayasu Kurata, MD, Noriko Yanagitani, MD, Hirokazu Taniguchi, MD, PhD, Shoichi Kuyama, MD, PhD, Junichi Shimizu, MD, PhD, Toshihide Yokoyama, MD, Naoko Shimada, MD, PhD, Tadashi Maeda, MD, Akihiro Tamiya, MD, Ayumi Uchiyama, MD, Kazuyoshi Imaizumi, MD, Takayuki Takahama, MD, PhD, Terufumi Kato, MD, Hidetoshi Hayashi, MD, PhD, Naoko Shiraiwa, MSc, Shigeyuki Toyoizumi, MSc, Hironori Kikkawa, PhD, Despina Thomaidou, MSc, Makoto Nishio, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 5, Pp 100508- (2023)
Introduction: Lorlatinib is an ALK tyrosine kinase inhibitor approved in Japan for the treatment of advanced ALK+ NSCLC. There has been little evidence about lorlatinib efficacy after first-line (1L) alectinib in clinical practice in Japan. Methods:
Externí odkaz:
https://doaj.org/article/bcbe60e4a4f34c35855ba34ee7b7698a
Autor:
Yasushi Yatabe, MD, PhD, Yasumasa Yoshiki, MPH, Koichi Matsumura, PhD, Kanae Togo, MSc, Hironori Kikkawa, PhD, Laura Iadeluca, PhD, MPH, Benjamin Li, PhD, Kazuto Nishio, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 3, Pp 100136- (2021)
Introduction: Diagnostic testing is important in determining appropriate treatment for individuals with lung cancer. In 2018, testing of five biomarkers (EGFR, ALK, ROS1, BRAF, programmed cell death-ligand 1 [PD-L1]) was approved in Japan. Informatio
Externí odkaz:
https://doaj.org/article/32ccbf8e9d9347f381ea1ab2194febed
Autor:
Yasushi Goto, Takehito Shukuya, Ai Murata, Hironori Kikkawa, Birol Emir, Robin Wiltshire, Satoru Miura
Publikováno v:
Cancer Science.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::48377fd8edc96fad3a753eabe6e8c923
https://doi.org/10.1111/cas.15777
https://doi.org/10.1111/cas.15777
Autor:
Kazuto Nishio, Yasushi Yatabe, Benjamin Li, L. Iadeluca, Hironori Kikkawa, Koichi Matsumura, Yasumasa Yoshiki, Kanae Togo
Publikováno v:
JTO Clinical and Research Reports
JTO Clinical and Research Reports, Vol 2, Iss 3, Pp 100136-(2021)
JTO Clinical and Research Reports, Vol 2, Iss 3, Pp 100136-(2021)
Introduction Diagnostic testing is important in determining appropriate treatment for individuals with lung cancer. In 2018, testing of five biomarkers (EGFR, ALK, ROS1, BRAF, programmed cell death-ligand 1 [PD-L1]) was approved in Japan. Information
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54bb94e525bdac171eb0c729ec1f0fda
http://europepmc.org/articles/PMC8474388
http://europepmc.org/articles/PMC8474388
Autor:
Megan S. Farris, Kazuhiko Nakagawa, Koichi Matsumura, Keith D. Wilner, Jasmina I Ivanova, Kelly A Larkin-Kaiser, Tayler Scory, Hironori Kikkawa
Publikováno v:
Future oncology (London, England). 17(1)
Background: Five EGFR-tyrosine kinase inhibitors ( EGFR TKIs) are currently available in the first-line setting for non-small-cell lung cancer (NSCLC) in Japan. The aim here was to compare the relative efficacy of EGFR TKIs in the Japanese population
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::128e3cdbac25cac88827364f96757c92
https://pubmed.ncbi.nlm.nih.gov/32959703
https://pubmed.ncbi.nlm.nih.gov/32959703
Autor:
Hironori Kikkawa, Yasuharu Yazawa, Motohiro Hoshino, Nobutomo Ikarashi, Fumiyo Sakuma, Kiyoshi Sugiyama
Publikováno v:
Journal of natural medicines. 74(4)
We previously revealed that Choreito, a traditional Kampo medicine, strongly inhibits bladder carcinogenesis promotion. We have also shown that Polyporus sclerotium, which is one of the crude drugs in Choreito, has the strongest bladder carcinogenesi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96c96f984204b44863a841d5bbd377cd
https://pubmed.ncbi.nlm.nih.gov/32488609
https://pubmed.ncbi.nlm.nih.gov/32488609
Autor:
Kanae Togo, Robin Wiltshire, Yasushi Goto, Elizabeth T. Masters, Yuichiro Ohe, Jack Mardekian, Nobuyuki Yamamoto, Hironori Kikkawa
Publikováno v:
Advances in therapy. 37(7)
The anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) alectinib was approved in Japan in 2014 for the treatment of ALK fusion gene-positive advanced non-small cell lung cancer (NSCLC). With the approvals of crizotinib in 2012 and cerit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3be86ec72edde0ddf1bad26f98dc803
https://pubmed.ncbi.nlm.nih.gov/32472430
https://pubmed.ncbi.nlm.nih.gov/32472430
Publikováno v:
Journal of Thoracic Oncology. 16:S1084
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4bd450df986b345cf44f2149ee957aee
https://doi.org/10.1016/j.jtho.2021.08.469
https://doi.org/10.1016/j.jtho.2021.08.469
Autor:
K. Ito, Kanae Togo, M. Pastel, Koichi Matsumura, Hironori Kikkawa, H. Kenmotsu, Jasmina I Ivanova, B. Li
Publikováno v:
Journal of Thoracic Oncology. 16:S560-S561
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dd934df570e092a8bcc5f07908930cde
https://doi.org/10.1016/j.jtho.2021.01.1007
https://doi.org/10.1016/j.jtho.2021.01.1007
Autor:
Kanae Togo, Birol Emir, Koichi Matsumura, L. Iadeluca, Hironori Kikkawa, Elizabeth T. Masters, L. Becnel, Yasushi Yatabe, R. Wiltshire, Kazuto Nishio, Yasumasa Yoshiki
Publikováno v:
Journal of Thoracic Oncology. 16:S162
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b57800764e24a1f41720d9dddbf6617d
https://doi.org/10.1016/j.jtho.2021.01.194
https://doi.org/10.1016/j.jtho.2021.01.194